you are here:

Ajanta Pharma Ltd.

BSE: 532331 | NSE: AJANTPHARM |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE031B01049 | SECTOR: Pharmaceuticals

BSE Live

May 07, 16:00
2018.60 19.55 (0.98%)
Volume
AVERAGE VOLUME
5-Day
16,004
10-Day
12,429
30-Day
9,263
6,780
  • Prev. Close

    1999.05

  • Open Price

    2000.00

  • Bid Price (Qty.)

    2013.00 (50)

  • Offer Price (Qty.)

    2018.60 (15)

NSE Live

May 07, 15:59
2017.55 16.45 (0.82%)
Volume
AVERAGE VOLUME
5-Day
314,180
10-Day
258,202
30-Day
201,271
244,450
  • Prev. Close

    2001.10

  • Open Price

    2009.00

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    2017.55 (133)

ANNOUNCEMENTS ON Ajanta Pharma

  • May 04, 2021 14:24 Source: BSE

    Ajanta Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Further to our communication dated 30th April 2021 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 30th April 2021 at 5.30 p.m. has been uploaded on the Company's website and can be accessed through the link http://ajantapharma.com/Results.aspx This is for your information and records please.

  • May 01, 2021 14:42 Source: BSE

    Ajanta Pharma - Announcement under Regulation 30 (LODR)-Newspaper Publication

    Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copies of financial results of the Company for the quarter and year ended 31st March 2021 published in the following newspapers on 1st May 2021: 1. Mumbai edition of Economic Times and 2. Mumbai edition of Maharashtra Times; This is for your information and record.

  • Apr 30, 2021 20:30 Source: BSE

    Ajanta Pharma - Audio Recording Of Earnings Call Conducted On 30Th April 2021

    Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 30th April 2021 at 5.30 p.m. has been uploaded on the Company's website and can be accessed through the link http://ajantapharma.com/Results.aspx Written transcript of the same will be submitted in due course. This is for your information and records please.

  • Apr 30, 2021 16:43 Source: BSE

    Ajanta Pharma - Grant Of Options

    This is to inform that the Nomination & Remuneration Committee of the Board has at its meeting held today granted options under Ajanta Pharma Share Based Incentive Plan 2019 as detailed below: 1. Total number of options granted - 3,000 2. Number of shares covered under options - 1 share per option 3. Exercise Period - Three months from vesting date This is for your information and record.

  • Apr 30, 2021 16:31 Source: BSE

    Ajanta Pharma - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

    This is to inform you that Ajanta Pharma Limited has subscribed to partnership interest in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP). The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Clause A(1) of Part A, Schedule III of the aforesaid regulations, is attached as per 'Annexure A'.

  • Apr 30, 2021 16:25 Source: BSE

    Ajanta Pharma -
    Outcome Of Board Meeting

    Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following: 1. Press Release; 2. Audited Consolidated Financial Results for the quarter and year ended 31st March 2021 along with Auditors' report with unmodified opinion; 3. Audited Standalone Financial Results for the quarter and year ended 31st March 2021 along with Auditors' report with unmodified opinion; 4. Investor's presentation. Separate disclosure under Regulation 30 is being filed shortly. We shall inform in due course, date of the 42nd Annual General Meeting to be held for the year ended 31st March 2021. Meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 4.00 p.m. Kindly take the above on your records.

  • Apr 30, 2021 16:09 Source: BSE

    Ajanta Pharma - Outcome Of The Board Meeting - Approve And Take On Record The Audited (Consolidated & Standalone) Financial Results Of The Company For The Quarter And Year Ended 31St March 2021

    Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following: 1. Press Release; 2. Audited Consolidated Financial Results for the quarter and year ended 31st March 2021 along with Auditors' report with unmodified opinion; 3. Audited Standalone Financial Results for the quarter and year ended 31st March 2021 along with Auditors' report with unmodified opinion; 4. Investor's presentation. Separate disclosure under Regulation 30 is being filed shortly. We shall inform in due course, date of the 42nd Annual General Meeting to be held for the year ended 31st March 2021. Meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 4.00 p.m. Kindly take the above on your records.

  • Apr 26, 2021 12:54 Source: BSE

    Ajanta Pharma - Schedule Of Earnings Conference Call Post Board Meeting

    Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 30th April 2021, post Board meeting.

  • Apr 22, 2021 12:35 Source: BSE

    Ajanta Pharma - Announcement under Regulation 30 (LODR)-Newspaper Publication

    Pursuant to Regulation 47 of the Listing Regulations, please find enclosed intimation about the meeting of Board of Directors of the Company to be held on Friday, 30th April 2021 published in the following newspapers on 22nd April 2021: 1. Mumbai edition of The Free Press Journal and 2. Mumbai edition of Navshakti; This is for your information and record.

  • Apr 21, 2021 14:29 Source: BSE

    Ajanta Pharma - Board Meeting Intimation for Considering And Approving Results

    AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Listing Regulations, we hereby inform that a Meeting of the Board of Directors of the Company will be held on Friday, 30th April 2021 to inter-alia consider and approve: a. Audited Financial Results (consolidated & standalone) of the Company for the quarter and year ended 31st March 2021; and b. Audited Financial Statements (consolidated & standalone) for the year ended 31st March 2021. You are requested to please take note of the same and disseminate to all concerned.

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : Apr 30, 2021
Remark : Audited Results